Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Yang, F ^a   Hu, M ^a   Lei, Q ^a   Xia, Y ^a   Zhu, Y ^a   Song, X ^a   Li, Y ^a   Jie, H ^a   Liu, C ^a   Xiong, Y ^a,b   Zuo, Z ^a   Zeng, A ^a   Yu, L ^a   Shen, G ^a   Wang, D ^c   Xie, Y ^a   Ye, T ^a   Wei, Y ^a  

^a SICHUAN UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; GELATINASE A; GELATINASE B; HYDROXYBENZOIC ACID DERIVATIVE; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; NIFUROXAZIDE; NITROFURAN DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; MCF 7 CELL LINE; MOUSE; PATHOLOGY; SECONDARY;

ANIMALS; ANTIDIARRHEALS; APOPTOSIS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYBENZOATES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MICE; NITROFURANS; STAT3 TRANSCRIPTION FACTOR;

EID: 84965086085     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/CDDIS.2015.63     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
2. Servick K. Breast cancer. Breast cancer: a world of differences. Science 2014; 343: 1452–1453.
3. Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HA. Progesterone metabolites regulate induction, growth, and suppression of estrogen-and progesterone receptor-negative human breast cell tumors. Breast Cancer Res 2013; 15: R38.
4. Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis 2014; 5: e1287.
5. Cetin I, Topcul M. Triple negative breast cancer. Asian Pac J Cancer Prev 2014; 15: 2427–2431.
6. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011; 17: 5275–5286.
7. Zhao Z, Lu P, Zhang H, Xu H, Gao N, Li M et al. Nestin positively regulates the Wnt/ss-catenin pathway and the proliferation, survival, and invasiveness of breast cancer stem cells. Breast Cancer Res 2014; 16: 408.
8. Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013; 15: R88.
9. Chen S, Han Q, Wang X, Yang M, Zhang Z, Li P et al. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/ Akt/FOXO3a signaling pathway. Cell Death Dis 2013; 4: e842.
10. Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 2004; 4: 97–105.
11. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005; 65: 5054–5062.
12. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005; 335: 292–299.
13. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013; 12: 611–629.
14. Walker SR, Xiang M, Frank DA. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 2014; 382: 616–621.
15. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314–1321.
16. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205: 2235–2249.
17. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506–2513.
18. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002; 21: 7611–7618.
19. Tell RW, Horvath CM. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. Proc Natl Acad Sci USA 2014; 111: 12787–12792.
20. Cataldo L, Chen NY, Yuan Q, Li W, Ramamoorthy P, Wagner TE et al. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 2000; 17: 1179–1185.
21. Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri FR et al. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PloS One 2013; 8: e74670.
22. Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L et al. The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PloS One 2014; 9: e85887.
23. Liu LJ, Leung KH, Chan DS, Wang YT, Ma DL, Leung CH. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis 2014; 5: e1293.
24. Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett 2014; 349: 8–14.
25. Kraljevic S, Stambrook PJ, Pavelic K. Accelerating drug discovery. EMBO Rep 2004; 5: 837–842.
26. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448: 645–646.
27. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008; 112: 5095–5102.
28. Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F et al. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 2012; 135: 445–458.
29. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5: 591–602.
30. Huang W, Dong Z, Wang F, Peng H, Liu JY, Zhang JT. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem Biol 2014; 9: 1188–1196.
31. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300–308.
32. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486–1493.
33. Wang YS, Li D, Shi HS, Wen YJ, Yang L, Xu N et al. Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin Cancer Res 2009; 15: 6901–6911.
34. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000; 60: 2710–2715.
35. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583–4594.
36. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162–174.
37. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011; 71: 6601–6610.
38. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009; 41: 40–47.
39. Watson CJ, Miller WR. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 1995; 71: 840–844.
40. Yue P, Haftchenary S, Gunning PT, Turkson J. A novel small-molecule inhibitor of Stat3 induces antitumor cell effects in human glioma and breast cancer cells. Cancer Res 2013; 73: 3253.
41. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543–1568.
42. Xia Y, Song X, Li D, Ye T, Xu Y, Lin H et al. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Sci Rep 2014; 4: 6031.
43. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362–374.
44. Sein TT, Thant AA, Hiraiwa Y, Amin AR, Sohara Y, Liu Y et al. A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and-9. Oncogene 2000; 19: 5539–5542.
45. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67–68.
46. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27: 925–932.
47. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011; 13: 227.
48. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16: 348–353.
49. Peng X, Xie G, Wang Z, Lin H, Zhou T, Xiang P et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis 2014; 5: e1143.
50. Ye T, Wei X, Yin T, Xia Y, Li D, Shao B et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat 2014; 143: 435–446.